Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2013 Filed Mar 8, 2013 15:29 UTC |
YOUNG JOHN DBusiness Unit President
|
SaleCommon Stock | 14,713 | $28.13 | $413,876.69 |
DisclosureSEC source: 0001225208-13-007040 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,520 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 16,801 | $28.11 | $472,276.11 |
DisclosureSEC source: 0001225208-13-007042 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,921 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 13,781 | $28.12 | $387,521.72 |
DisclosureSEC source: 0001225208-13-007042 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,722 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
SaleCommon Stock | 56,064 | $28.14 | $1,577,640.96 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 8 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,076 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
SaleCommon Stock | 13,970 | $28.15 | $393,255.50 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 7 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,140 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
SaleCommon Stock | 13,800 | $28.11 | $387,918.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 6 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,110 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
SaleCommon Stock | 13,000 | $28.12 | $365,560.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 5 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,910 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
SaleCommon Stock | 9,500 | $28.13 | $267,235.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 4 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,910 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
SaleCommon Stock | 4,100 | $28.17 | $115,497.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 3 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,410 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
SaleCommon Stock | 2,430 | $28.16 | $68,428.80 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,510 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
SaleCommon Stock | 500 | $28.10 | $14,050.00 |
DisclosureSEC source: 0001225208-13-007043 · doc4.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,940 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 15:30 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 53,196 | $28.13 | $1,496,403.48 |
DisclosureSEC source: 0001225208-13-007044 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,390 Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 127,971 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · derivative · entry 9 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,971 Underlying: Common Stock · 127,971 shares Expires 2020-02-28 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 154,185 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · derivative · entry 8 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,185 Underlying: Common Stock · 154,185 shares Expires 2018-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
Exercise / conversionStock Appreciation Rights · Derivative | 40,629 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · derivative · entry 7 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,629 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
Tax withholdingCommon Stock | 41,196 | $27.37 | $1,127,534.52 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · nonDerivative · entry 5 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,440 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
Tax withholdingCommon Stock | 24,743 | $27.37 | $677,215.91 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · nonDerivative · entry 4 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,636 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantCommon Stock | 26,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · nonDerivative · entry 3 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,379 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantCommon Stock | 44,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · nonDerivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,299 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:40 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
Exercise / conversionCommon Stock | 47,189 | $22.55 | $1,064,111.95 |
DisclosureSEC source: 0001225208-13-006456 · doc4.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:49 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 27,422 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006457 · doc4.xml · derivative · entry 9 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,422 Underlying: Common Stock · 27,422 shares Expires 2020-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:49 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 33,040 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006457 · doc4.xml · derivative · entry 8 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,040 Underlying: Common Stock · 33,040 shares Expires 2018-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:49 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionStock Appreciation Rights · Derivative | 38,443 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006457 · doc4.xml · derivative · entry 7 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,443 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:49 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 36,560 | $27.37 | $1,000,647.20 |
DisclosureSEC source: 0001225208-13-006457 · doc4.xml · nonDerivative · entry 5 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,290 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:49 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 5,253 | $27.37 | $143,774.61 |
DisclosureSEC source: 0001225208-13-006457 · doc4.xml · nonDerivative · entry 4 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,850 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:49 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 5,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006457 · doc4.xml · nonDerivative · entry 3 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,103 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:49 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 14,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006457 · doc4.xml · nonDerivative · entry 2 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,514 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:49 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionCommon Stock | 44,650 | $22.55 | $1,006,857.50 |
DisclosureSEC source: 0001225208-13-006457 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:54 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 173,675 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006458 · doc4.xml · derivative · entry 9 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,675 Underlying: Common Stock · 173,675 shares Expires 2020-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:54 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 209,251 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006458 · doc4.xml · derivative · entry 8 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,251 Underlying: Common Stock · 209,251 shares Expires 2018-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:54 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 168,739 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006458 · doc4.xml · derivative · entry 7 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,739 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:54 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 168,696 | $27.37 | $4,617,209.52 |
DisclosureSEC source: 0001225208-13-006458 · doc4.xml · nonDerivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,338 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:54 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 43,838 | $27.37 | $1,199,846.06 |
DisclosureSEC source: 0001225208-13-006458 · doc4.xml · nonDerivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,034 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:54 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantCommon Stock | 35,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006458 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 796,872 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:54 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantCommon Stock | 85,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006458 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761,477 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 23:54 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionCommon Stock | 195,985 | $22.55 | $4,419,461.75 |
DisclosureSEC source: 0001225208-13-006458 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 164,534 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006459 · doc4.xml · derivative · entry 7 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,534 Underlying: Common Stock · 164,534 shares Expires 2020-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 198,238 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006459 · doc4.xml · derivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,238 Underlying: Common Stock · 198,238 shares Expires 2018-02-28 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Dolsten MikaelPresident R&D
|
GrantPhantom Stock Units SSP · Derivative | 78 | $27.37 | $2,134.86 |
DisclosureSEC source: 0001225208-13-006459 · doc4.xml · derivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,773 Underlying: Common Stock · 78 shares Expires not disclosed F4 · derivative.exercise_price: Each unit represents one phantom share of common stock. F5 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F5 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 32,565 | $27.37 | $891,304.05 |
DisclosureSEC source: 0001225208-13-006459 · doc4.xml · nonDerivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,503 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Dolsten MikaelPresident R&D
|
GrantCommon Stock | 33,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006459 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,068 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Dolsten MikaelPresident R&D
|
GrantCommon Stock | 63,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006459 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,536 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Germano Geno JBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 137,112 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006460 · doc4.xml · derivative · entry 8 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,112 Underlying: Common Stock · 137,112 shares Expires 2020-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Germano Geno JBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 165,198 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006460 · doc4.xml · derivative · entry 7 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,198 Underlying: Common Stock · 165,198 shares Expires 2018-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Germano Geno JBusiness Unit President
|
GrantPhantom Stock Units SSP · Derivative | 12 | $27.37 | $328.44 |
DisclosureSEC source: 0001225208-13-006460 · doc4.xml · derivative · entry 6 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,317 Underlying: Common Stock · 12 shares Expires not disclosed F5 · derivative.exercise_price: Each unit represents one phantom share of common stock. F6 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F6 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Germano Geno JBusiness Unit President
|
Tax withholdingCommon Stock | 17,341 | $27.37 | $474,623.17 |
DisclosureSEC source: 0001225208-13-006460 · doc4.xml · nonDerivative · entry 3 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,392 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Germano Geno JBusiness Unit President
|
GrantCommon Stock | 27,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006460 · doc4.xml · nonDerivative · entry 2 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,733 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:02 UTC |
Germano Geno JBusiness Unit President
|
GrantCommon Stock | 35,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006460 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,790 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 84,552 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006461 · doc4.xml · derivative · entry 9 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,552 Underlying: Common Stock · 84,552 shares Expires 2020-02-28 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 101,872 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006461 · doc4.xml · derivative · entry 8 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,872 Underlying: Common Stock · 101,872 shares Expires 2018-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.